

## **APPENDIX A**

## "MARKED THE PARAGRAPHS ILLUSTRATING THE AMENDMENTS MADE TO THE

## SPECIFICATION OF 09/775,856 WITH ENTRY OF THIS AMENDMENT

## ABSTRACT OF THE DISCLOSURE

The application relates to the purification and characterization of a family of A-type inositolphosphoglycans (IPGs) from human liver and placenta. These substances are shown to have the biological activity associated with A-type IPG fractions, namely regulating lipogenic activity and inhibiting cAMP dependent protein kinase. The characterization of the compounds demonstrates that they contain metal ions, in particular Zn<sup>2+</sup>, and optionally phosphate. The compounds and their antagonists have uses as pharmaceuticals, e.g. for the treatment of diabetes, and in screening for synthetic analogs.